England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Executive Summary
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.